Compare Novavax Inc (NVAX) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs VanEck Vietnam ETF — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while VanEck Vietnam ETF trades at $16.72 (market cap $469.76M). The key difference: Novavax Inc is far larger — about 3.9× VanEck Vietnam ETF's market cap, and Novavax Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and VanEck Vietnam ETF for 51 Days on average.
| NVAX | VNM | |
|---|---|---|
Market Cap | $1.82B | $469.76M |
Volume | 6,198,505 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $12.56 | $19.80 |
52-Week Low | $6.22 | $16.34 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
VNM trades at $16.72, down 0.89% today, with a bearish technical signal from moving averages but bullish momentum from oscillators. The stock faces sector concentration risks in real estate and financials while benefiting from Vietnam's potential US trade deal progress. Key support and resistance cluster around $17, with RSI levels indicating potential oversold conditions.
The outlook remains cautious due to sector headwinds and interest rate sensitivity, though fair valuation and macroeconomic growth prospects offer long-term potential. Near-term performance depends on trade developments and sector stability, with institutional sentiment mixed on timing and risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
